Jin Han

Jin Han

Auto-generated profile, based on publicly available information

Jin Han

College of Pharmacy University of Illinois at Chicago Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Immunity
Verified
Journal Article
Closed access
ASAdam K. Savage
Adam K. Savage
MCMichael G. Constantinides
Michael G. Constantinides
JHJin Han
Jin Han
DPDamien Picard
Damien Picard
EMEmmanuel Martin
Emmanuel Martin
ABAlbert Bendelac
Albert Bendelac

19 November 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JSJr-Wen Shui
Jr-Wen Shui
JBJonathan S Boomer
Jonathan S Boomer
JHJin Han
Jin Han
JXJun Xu
Jun Xu
GDGregory A Dement
Gregory A Dement
TTTse-Hua Tan
Tse-Hua Tan

20 November 2011 in Nature Immunology
Verified
Journal Article
Open access
PDF file
ADAnke Di
Anke Di
XGXiao-Pei Gao
Xiao-Pei Gao
FQFeng Qian
Feng Qian
TKTakeshi Kawamura
Takeshi Kawamura
JHJin Han
Jin Han
AMAsrar B Malik
Asrar B Malik
The generation of reactive oxygen species needs to be carefully controlled to prevent tissue injury. Malik and colleagues identify a negative feedback mechanism for such production involving the cation channel TRPM2. The NADPH oxidase activity of phagocytes and its generation of reactive oxygen species (ROS) is critical for host defense, but ROS overproduction can also lead to inflammation and tissue injury. Here we report that TRPM2, a nonselective and redox-sensitive cation channel, inhibited ROS production in phagocytic cells and prevented endotoxin-induced lung inflammation in mice. TRPM2-deficient mice challenged with endotoxin (lipopolysaccharide) had an enhanced inflammatory response and diminished survival relative to that of wild-type mice challenged with endotoxin. TRPM2 functioned by dampening NADPH oxidase–mediated ROS production through depolarization of the plasma membrane in phagocytes. As ROS also activate TRPM2, our findings establish a negative feedback mechanism for the inactivation of ROS production through inhibition of the membrane potential–sensitive NADPH oxidase.

26 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MDMarei Dose
Marei Dose
BSBarry P. Sleckman
Barry P. Sleckman
JHJin Han
Jin Han
ABAndrea L. Bredemeyer
Andrea L. Bredemeyer
ABAlbert Bendelac
Albert Bendelac
FGFotini Gounari
Fotini Gounari
The molecular requirements for invariant Vα14-bearing natural killer T cells (iNKT) in the thymus are poorly understood. A minute population of ≈500 newly selected CD69 + CD24 + stage 0 (ST0) iNKT cells gives rise to ≈100 times more CD44 neg/lo CD24 − stage 1 (ST1) cells, which then generate similar frequencies of CD44 hi CD24 − stage 2 (ST2) and mature iNKT cells. Although the increased number of ST1 compared with ST0 cells indicates the initiation of a proliferation wave in the very early stages of iNKT cell development, details about the controlling mechanism are currently lacking. Here, we show that the transcription factor c-Myc is required for iNKT cell development. Conditional ablation of c-Myc in double-positive thymocytes specifically impacted iNKT but not conventional T cell development. Within the iNKT population, a progressive reduction of iNKT cells was observed starting at ST1 (≈50-fold) and ST2 (≈350-fold), with a complete lack of mature cells in thymus, spleen, and liver. ST0/ST1 c-Myc-deficient iNKT cells showed reduced proliferation. In contrast, annexin V staining did not reveal increased apoptosis, and transgenic overexpression of BCL-2 did not rescue iNKT cell development in c-Myc-deficient mice. Moreover, expression of known iNKT differentiation factors such as Plzf and Gata3 was not dramatically altered. These, findings provide compelling evidence that c-Myc mediates an intrathymic proliferation wave immediately after agonist selection of iNKT cells and illustrate the importance of this expansion for the generation of mature iNKT cells in vivo.

8 May 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
FHFaiz A. Hussain
Faiz A. Hussain
FNFranklin U. Njoku
Franklin U. Njoku
SSSantosh L. Saraf
Santosh L. Saraf
RMRobert E. Molokie
Robert E. Molokie
VGVictor R. Gordeuk
Victor R. Gordeuk
JHJin Han
Jin Han
Severe acute respiratory syndrome coronavirus 2, also known as COVID‐19, has spread to 184 countries with almost 1.5 million cases as of mid‐April 2020 since first reported (1). The clinical features of this disease are not completely understood, however severe illness is thought to predominantly occur in adults with advanced age and those with underlying comorbidities (2). Sickle cell disease (SCD), an immunocompromised condition, puts patients at higher risk for respiratory infections and subsequent pulmonary complications such as acute chest syndrome (ACS) (3).

23 February 2009 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FTFangming Tang
Fangming Tang
ZCZhangguo Chen
Zhangguo Chen
CCCezary Ciszewski
Cezary Ciszewski
MSMala Setty
Mala Setty
JSJason Solus
Jason Solus
BJBana Jabri
Bana Jabri
IL-15 and NKG2D promote autoimmunity and celiac disease by arming cytotoxic T lymphocytes (CTLs) to cause tissue destruction. However, the downstream signaling events underlying these functional properties remain unclear. Here, we identify cytosolic phospholipase A2 (cPLA2) as a central molecule in NKG2D-mediated cytolysis in CTLs. Furthermore, we report that NKG2D induces, upon recognition of MIC+ target cells, the release of arachidonic acid (AA) by CTLs to promote tissue inflammation in association with target killing. Interestingly, IL-15, which licenses NKG2D-mediated lymphokine killer activity in CTLs, cooperates with NKG2D to induce cPLA2 activation and AA release. Finally, cPLA2 activation in intraepithelial CTLs of celiac patients provides an in vivo pathophysiological dimension to cPLA2 activation in CTLs. These results reveal an unrecognized link between NKG2D and tissue inflammation, which may underlie the emerging role of NKG2D in various immunopathological conditions and define new therapeutic targets.